6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
include	VBP	include	include	includ	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
663	CD	663	663	663	N	O
-	:	-	-	-	N	O
0412	CD	0412	0412	0412	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

STENDRA	NNP	stendra	stendra	stendra	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
2215	CD	2215	2215	2215	N	O
men	NNS	men	men	men	N	O
during	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
493	CD	493	493	493	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
153	CD	153	153	153	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
three	CD	three	three	three	N	O
randomized	NNS	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
lasting	VBG	lasting	lasting	last	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
duration	NN	duration	duration	durat	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
56.4	CD	56.4	56.4	56.4	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
from	IN	from	from	from	N	O
23	CD	23	23	23	N	O
to	TO	to	to	to	N	O
88	CD	88	88	88	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

83.9%	CD	83.9%	83.9%	83.9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
13.8%	CD	13.8%	13.8%	13.8%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
,	,	,	,	,	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
.	.	.	.	.	N	O

41.1%	CD	41.1%	41.1%	41.1%	N	O
were	VBD	were	were	were	N	O
current	JJ	current	current	current	N	O
or	CC	or	or	or	N	O
previous	JJ	previous	previous	previou	N	O
smokers	NNS	smokers	smoker	smoker	N	O
.	.	.	.	.	N	O

30.6%	CD	30.6%	30.6%	30.6%	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
rate	NN	rate	rate	rate	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
,	,	,	,	,	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
when	WRB	when	when	when	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
was	VBD	was	wa	wa	N	O
taken	VBN	taken	taken	taken	N	O
as	RB	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
(	(	(	(	(	N	O
on	IN	on	on	on	N	O
an	DT	an	an	an	N	O
as	IN	as	a	as	N	O
-	:	-	-	-	N	O
needed	JJ	needed	needed	need	N	O
basis	NN	basis	basis	basi	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
these	DT	these	these	these	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
Greater	NNP	greater	greater	greater	N	O
Than	NNP	than	than	than	N	O
or	CC	or	or	or	N	O
Equal	NNP	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
From	NNP	from	from	from	N	O
3	CD	3	3	3	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Lasting	VBG	lasting	lasting	last	N	O
3	CD	3	3	3	N	O
Months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
Use	NNP	use	use	use	N	O
as	IN	as	a	as	N	O
Needed	NNP	needed	needed	need	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
349	CD	349	349	349	N	O
)	)	)	)	)	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
217	CD	217	217	217	N	O
)	)	)	)	)	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
349	CD	349	349	349	N	O
)	)	)	)	)	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
352	CD	352	352	352	N	O
)	)	)	)	)	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

1.7%	CD	1.7%	1.7%	1.7%	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
6.9%	CD	6.9%	6.9%	6.9%	N	O
10.5%	CD	10.5%	10.5%	10.5%	N	O

Flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
4.3%	CD	4.3%	4.3%	4.3%	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
2.9%	CD	2.9%	2.9%	2.9%	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
2.9%	CD	2.9%	2.9%	2.9%	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
dose	NN	dose	dose	dose	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
URI	NNP	uri	uri	uri	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinus	JJ	sinus	sinus	sinu	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
extension	NN	extension	extension	extens	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
712	CD	712	712	712	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
participated	VBD	participated	participated	particip	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
extension	NN	extension	extension	extens	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
56.4	CD	56.4	56.4	56.4	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
from	IN	from	from	from	N	O
23	CD	23	23	23	N	O
to	TO	to	to	to	N	O
88	CD	88	88	88	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
rate	NN	rate	rate	rate	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
eligible	JJ	eligible	eligible	elig	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
initially	RB	initially	initially	initi	N	O
assigned	VBN	assigned	assigned	assign	N	O
to	TO	to	to	to	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
point	NN	point	point	point	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
could	MD	could	could	could	N	O
request	VB	request	request	request	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
increased	VBD	increased	increased	increas	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
decreased	VBN	decreased	decreased	decreas	N	O
to	TO	to	to	to	N	O
50	CD	50	50	50	N	O
mg	NNS	mg	mg	mg	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
their	PRP$	their	their	their	N	O
individual	JJ	individual	individual	individu	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
total	JJ	total	total	total	N	O
,	,	,	,	,	N	O
536	CD	536	536	536	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
75%	CD	75%	75%	75%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
increased	VBD	increased	increased	increas	N	O
their	PRP$	their	their	their	N	O
dose	NN	dose	dose	dose	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
and	CC	and	and	and	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
reduced	VBD	reduced	reduced	reduc	N	O
their	PRP$	their	their	their	N	O
dose	NN	dose	dose	dose	N	O
to	TO	to	to	to	N	O
50	CD	50	50	50	N	O
mg	NNS	mg	mg	mg	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
when	WRB	when	when	when	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
was	VBD	was	wa	wa	N	O
taken	VBN	taken	taken	taken	N	O
as	RB	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
(	(	(	(	(	N	O
on	IN	on	on	on	N	O
an	DT	an	an	an	N	O
as	IN	as	a	as	N	O
-	:	-	-	-	N	O
needed	JJ	needed	needed	need	N	O
basis	NN	basis	basis	basi	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
Greater	NNP	greater	greater	greater	N	O
Than	NNP	than	than	than	N	O
or	CC	or	or	or	N	O
Equal	NNP	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
With	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
Open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
Label	NNP	label	label	label	N	O
Extension	NNP	extension	extension	extens	N	O
Trial	NNP	trial	trial	trial	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
711	CD	711	711	711	N	O
)	)	)	)	)	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

5.6%	CD	5.6%	5.6%	5.6%	N	O

Flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
3.5%	CD	3.5%	3.5%	3.5%	N	O

Nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
3.4%	CD	3.4%	3.4%	3.4%	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
2.1%	CD	2.1%	2.1%	2.1%	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
extension	NN	extension	extension	extens	N	O
study	NN	study	study	studi	N	O
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
URI	NNP	uri	uri	uri	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
influenza	JJ	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

following	VBG	following	following	follow	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
month	NN	month	month	month	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
extension	NN	extension	extension	extens	N	O
study	NN	study	study	studi	N	O
lasting	VBG	lasting	lasting	last	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
is	VBZ	is	is	is	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
.	.	.	.	.	N	O

Excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
this	DT	this	this	thi	N	O
list	NN	list	list	list	N	O
are	VBP	are	are	are	N	O
those	DT	those	those	those	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
minor	JJ	minor	minor	minor	N	O
,	,	,	,	,	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	O
plausible	JJ	plausible	plausible	plausibl	N	O
relation	NN	relation	relation	relat	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
reports	NNS	reports	report	report	N	O
too	RB	too	too	too	N	O
imprecise	VBP	imprecise	imprecise	imprecis	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
.	.	.	.	.	N	O

Body	NN	body	body	bodi	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
whole	JJ	whole	whole	whole	N	O
-	:	-	-	-	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
-	:	-	-	-	N	O
angina	NN	angina	angina	angina	N	B-AdverseReaction
,	,	,	,	,	N	O
unstable	JJ	unstable	unstable	unstabl	N	B-AdverseReaction
angina	NN	angina	angina	angina	N	I-AdverseReaction
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction

Digestive	NNP	digestive	digestive	digest	N	O
-	:	-	-	-	N	O
gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastroesophageal	JJ	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
stomach	NN	stomach	stomach	stomach	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
-	:	-	-	-	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
-	:	-	-	-	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
-	:	-	-	-	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	JJ	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	JJ	exertional	exertional	exert	N	I-AdverseReaction
,	,	,	,	,	N	O
epistaxis	JJ	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
wheezing	VBG	wheezing	wheezing	wheez	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Appendages	NNP	appendages	appendage	appendag	N	O
-	:	-	-	-	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction

Urogenital	JJ	urogenital	urogenital	urogenit	N	O
-	:	-	-	-	N	O
balanitis	NN	balanitis	balanitis	balan	Y	B-AdverseReaction
,	,	,	,	,	N	O
erection	NN	erection	erection	erect	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephrolithiasis	NN	nephrolithiasis	nephrolithiasis	nephrolithiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pollakiuria	NN	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
lasting	VBG	lasting	lasting	last	N	O
up	RP	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
in	IN	in	in	in	N	O
298	CD	298	298	298	N	O
men	NNS	men	men	men	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
undergone	JJ	undergone	undergone	undergon	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
nerve	NN	nerve	nerve	nerv	N	O
-	:	-	-	-	N	O
sparing	VBG	sparing	sparing	spare	N	O
radical	JJ	radical	radical	radic	N	O
prostatectomy	NN	prostatectomy	prostatectomy	prostatectomi	Y	O
for	IN	for	for	for	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
58.4	CD	58.4	58.4	58.4	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
40	CD	40	40	40	N	O
-	:	-	-	-	N	O
70	CD	70	70	70	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
Equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Lasting	NNP	lasting	lasting	last	N	O
3	CD	3	3	3	N	O
Months	NNP	months	month	month	N	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
Who	NNP	who	who	who	N	O
Underwent	NNP	underwent	underwent	underw	N	O
Bilateral	NNP	bilateral	bilateral	bilater	N	O
Nerve	NNP	nerve	nerve	nerv	N	O
-	:	-	-	-	N	O
Sparing	VBG	sparing	sparing	spare	N	O
Radical	JJ	radical	radical	radic	N	O
Prostatectomy	NN	prostatectomy	prostatectomy	prostatectomi	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

1.0%	CD	1.0%	1.0%	1.0%	N	O
8.1%	CD	8.1%	8.1%	8.1%	N	O
12.1%	CD	12.1%	12.1%	12.1%	N	O

Flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
10.1%	CD	10.1%	10.1%	10.1%	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
1.0%	CD	1.0%	1.0%	1.0%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
1.0%	CD	1.0%	1.0%	1.0%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O

Electrocardiogram	NNP	electrocardiogram	electrocardiogram	electrocardiogram	Y	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O

A	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
study	NN	study	study	studi	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
435	CD	435	435	435	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
58.2	CD	58.2	58.2	58.2	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
24	CD	24	24	24	N	O
to	TO	to	to	to	N	O
86	CD	86	86	86	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
erection	NN	erection	erection	erect	N	O
sufficient	NN	sufficient	sufficient	suffici	N	O
for	IN	for	for	for	N	O
sexual	JJ	sexual	sexual	sexual	N	O
intercourse	NN	intercourse	intercourse	intercours	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Lasting	NNP	lasting	lasting	last	N	O
2	CD	2	2	2	N	O
Months	NNP	months	month	month	N	O
to	TO	to	to	to	N	O
Determine	VB	determine	determine	determin	N	O
the	DT	the	the	the	N	O
Time	NNP	time	time	time	N	O
to	TO	to	to	to	N	O
Onset	NNP	onset	onset	onset	N	O
of	IN	of	of	of	N	O
Effect	NNP	effect	effect	effect	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebon	NNP	placebon	placebon	placebon	N	O
143	CD	143	143	143	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
100	CD	100	100	100	N	O
mgn	NN	mgn	mgn	mgn	N	O
146	CD	146	146	146	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
200	CD	200	200	200	N	O
mgn	NN	mgn	mgn	mgn	N	O
146	CD	146	146	146	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

0.7%	CD	0.7%	0.7%	0.7%	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
8.9%	CD	8.9%	8.9%	8.9%	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O

Gastroenteritis	NNP	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
viral	JJ	viral	viral	viral	N	I-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O

Across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
subject	NN	subject	subject	subject	N	O
reported	VBD	reported	reported	report	N	O
a	DT	a	a	a	N	O
change	NN	change	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
color	NN	color	color	color	N	I-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

Ophthalmologic	NN	ophthalmologic	ophthalmologic	ophthalmolog	N	O
:	:	:	:	:	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
arteritic	JJ	arteritic	arteritic	arterit	N	I-AdverseReaction
anterior	JJ	anterior	anterior	anterior	N	I-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
optic	JJ	optic	optic	optic	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
NAION	NNP	naion	naion	naion	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
rarely	RB	rarely	rarely	rare	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
in	IN	in	in	in	N	O
temporal	JJ	temporal	temporal	tempor	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
phosphodiesterase	NN	phosphodiesterase	phosphodiesterase	phosphodiesteras	N	B-DrugClass
type	NN	type	type	type	N	I-DrugClass
5	CD	5	5	5	N	I-DrugClass
(	(	(	(	(	N	I-DrugClass
PDE5	NNP	pde5	pde5	pde5	N	I-DrugClass
)	)	)	)	)	N	I-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
all	DT	all	all	all	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
underlying	JJ	underlying	underlying	underli	N	O
anatomic	JJ	anatomic	anatomic	anatom	N	O
or	CC	or	or	or	N	O
vascular	JJ	vascular	vascular	vascular	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
NAION	NNP	naion	naion	naion	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
necessarily	RB	necessarily	necessarily	necessarili	N	O
limited	VBN	limited	limited	limit	N	O
to	TO	to	to	to	N	O
:	:	:	:	:	N	O
low	JJ	low	low	low	N	O
cup	NN	cup	cup	cup	N	O
to	TO	to	to	to	N	O
disc	VB	disc	disc	disc	N	O
ratio	NN	ratio	ratio	ratio	N	O
(	(	(	(	(	N	O
"	NNP	"	"	"	N	O
crowded	VBD	crowded	crowded	crowd	N	O
disc	JJ	disc	disc	disc	N	O
"	NNP	"	"	"	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
age	NN	age	age	age	N	O
over	IN	over	over	over	N	O
50	CD	50	50	50	N	O
,	,	,	,	,	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
coronary	JJ	coronary	coronary	coronari	N	O
artery	NN	artery	artery	arteri	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
hyperlipidemia	NN	hyperlipidemia	hyperlipidemia	hyperlipidemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
smoking	NN	smoking	smoking	smoke	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
related	VBN	related	related	relat	N	O
directly	RB	directly	directly	directli	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
underlying	JJ	underlying	underlying	underli	N	O
vascular	JJ	vascular	vascular	vascular	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
or	CC	or	or	or	N	O
anatomical	JJ	anatomical	anatomical	anatom	N	O
defects	NNS	defects	defect	defect	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
andPatient	NN	andpatient	andpatient	andpati	N	O
Counseling	VBG	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17.6	CD	17.6	17.6	17.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

Evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
erectile	JJ	erectile	erectile	erectil	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
(	(	(	(	(	N	O
ED	NNP	ed	ed	ed	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
assessment	NN	assessment	assessment	assess	N	O
to	TO	to	to	to	N	O
identify	VB	identify	identify	identifi	N	O
potential	JJ	potential	potential	potenti	N	O
underlying	JJ	underlying	underlying	underli	N	O
causes	NNS	causes	cause	caus	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
treatment	NN	treatment	treatment	treatment	N	O
options	NNS	options	option	option	N	O
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
note	VB	note	note	note	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
if	IN	if	if	if	N	O
sexual	JJ	sexual	sexual	sexual	N	O
activity	NN	activity	activity	activ	N	O
is	VBZ	is	is	is	N	O
inadvisable	JJ	inadvisable	inadvisable	inadvis	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
status	NN	status	status	statu	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
reason	NN	reason	reason	reason	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
with	IN	with	with	with	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
antihypertensives	NNS	antihypertensives	antihypertensive	antihypertens	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
substantial	JJ	substantial	substantial	substanti	N	O
amounts	NNS	amounts	amount	amount	N	O
of	IN	of	of	of	N	O
alcohol	NN	alcohol	alcohol	alcohol	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	O
units	NNS	units	unit	unit	N	O
)	)	)	)	)	N	O
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
,	,	,	,	,	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
seek	VB	seek	seek	seek	N	O
emergency	NN	emergency	emergency	emerg	N	O
treatment	NN	treatment	treatment	treatment	N	O
if	IN	if	if	if	N	O
an	DT	an	an	an	N	O
erection	NN	erection	erection	erect	N	O
lasts	VBZ	lasts	last	last	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	O
hours	NNS	hours	hour	hour	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
stop	VB	stop	stop	stop	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
and	CC	and	and	and	N	O
seek	VB	seek	seek	seek	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
sudden	JJ	sudden	sudden	sudden	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
occurs	NNS	occurs	occurs	occur	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
both	DT	both	both	both	N	O
eyes	NNS	eyes	eye	eye	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
Non	NNP	non	non	non	N	O
Arteritic	NNP	arteritic	arteritic	arterit	N	O
Ischemic	NNP	ischemic	ischemic	ischem	N	O
Optic	NNP	optic	optic	optic	N	O
Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	O
(	(	(	(	(	N	O
NAION	NNP	naion	naion	naion	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

STENDRA	NNP	stendra	stendra	stendra	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
only	RB	only	only	onli	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
anticipated	JJ	anticipated	anticipated	anticip	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
"	NN	"	"	"	N	O
crowded	VBN	crowded	crowded	crowd	N	O
"	NNP	"	"	"	N	O
optic	JJ	optic	optic	optic	N	O
disc	NN	disc	disc	disc	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
stop	VB	stop	stop	stop	N	O
taking	VBG	taking	taking	take	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
and	CC	and	and	and	N	O
seek	JJ	seek	seek	seek	N	O
prompt	NN	prompt	prompt	prompt	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
sudden	JJ	sudden	sudden	sudden	N	O
decrease	NN	decrease	decrease	decreas	N	O
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
hearing	NN	hearing	hearing	hear	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Risks	NNS	risks	risk	risk	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
risk	NN	risk	risk	risk	N	I-AdverseReaction
during	IN	during	during	dure	N	O
sexual	JJ	sexual	sexual	sexual	N	O
activity	NN	activity	activity	activ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
treatments	NNS	treatments	treatment	treatment	N	O
for	IN	for	for	for	N	O
ED	NNP	ed	ed	ed	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
men	NNS	men	men	men	N	O
for	IN	for	for	for	N	O
whom	WP	whom	whom	whom	N	O
sexual	JJ	sexual	sexual	sexual	N	O
activity	NN	activity	activity	activ	N	O
is	VBZ	is	is	is	N	O
inadvisable	JJ	inadvisable	inadvisable	inadvis	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
underlying	JJ	underlying	underlying	underli	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
status	NN	status	status	statu	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
left	JJ	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
outflow	JJ	outflow	outflow	outflow	N	O
obstruction	NN	obstruction	obstruction	obstruct	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
aortic	JJ	aortic	aortic	aortic	N	O
stenosis	NN	stenosis	stenosis	stenosi	Y	O
,	,	,	,	,	N	O
idiopathic	JJ	idiopathic	idiopathic	idiopath	N	O
hypertrophic	JJ	hypertrophic	hypertrophic	hypertroph	N	O
subaortic	JJ	subaortic	subaortic	subaort	N	O
stenosis	NN	stenosis	stenosis	stenosi	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
severely	RB	severely	severely	sever	N	O
impaired	JJ	impaired	impaired	impair	N	O
autonomic	JJ	autonomic	autonomic	autonom	N	O
control	NN	control	control	control	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
particularly	RB	particularly	particularly	particularli	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
actions	NNS	actions	action	action	N	O
of	IN	of	of	of	N	O
vasodilators	NNS	vasodilators	vasodilator	vasodil	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
groups	NNS	groups	group	group	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
therefore	RB	therefore	therefore	therefor	N	O
until	IN	until	until	until	N	O
further	JJ	further	further	further	N	O
information	NN	information	information	inform	N	O
is	VBZ	is	is	is	N	O
available	JJ	available	available	avail	N	O
,	,	,	,	,	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
groups	NNS	groups	group	group	N	O
:	:	:	:	:	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
suffered	VBN	suffered	suffered	suffer	N	O
a	DT	a	a	a	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	O
,	,	,	,	,	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
coronary	JJ	coronary	coronary	coronari	N	O
revascularization	NN	revascularization	revascularization	revascular	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
;	:	;	;	;	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
resting	VBG	resting	resting	rest	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
(	(	(	(	(	N	O
blood	JJ	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
90	CD	90	90	90	N	O
50	CD	50	50	50	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
(	(	(	(	(	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
170	CD	170	170	170	N	O
100	CD	100	100	100	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
unstable	JJ	unstable	unstable	unstabl	N	O
angina	NN	angina	angina	angina	N	O
,	,	,	,	,	N	O
angina	NN	angina	angina	angina	N	O
with	IN	with	with	with	N	O
sexual	JJ	sexual	sexual	sexual	N	O
intercourse	NN	intercourse	intercourse	intercours	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
New	NNP	new	new	new	N	O
York	NNP	york	york	york	N	O
Heart	NNP	heart	heart	heart	N	O
Association	NNP	association	association	associ	N	O
Class	NNP	class	class	class	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
has	VBZ	has	ha	ha	N	O
systemic	JJ	systemic	systemic	system	N	O
vasodilatory	NN	vasodilatory	vasodilatory	vasodilatori	N	O
properties	NNS	properties	property	properti	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
augment	VB	augment	augment	augment	N	O
the	DT	the	the	the	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
-	:	-	-	-	N	O
lowering	VBG	lowering	lowering	lower	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
medications	NNS	medications	medication	medic	N	O
.	.	.	.	.	N	O

STENDRA	NNP	stendra	stendra	stendra	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
transient	NN	transient	transient	transient	N	B-AdverseReaction
decreases	NNS	decreases	decrease	decreas	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
sitting	VBG	sitting	sitting	sit	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
in	IN	in	in	in	N	O
healthy	JJ	healthy	healthy	healthi	N	O
volunteers	NNS	volunteers	volunteer	volunt	N	O
of	IN	of	of	of	N	O
8.0	CD	8.0	8.0	8.0	N	B-Severity
mmHg	NNS	mmhg	mmhg	mmhg	N	I-Severity
systolic	JJ	systolic	systolic	systol	N	I-Severity
and	CC	and	and	and	N	I-Severity
3.3	CD	3.3	3.3	3.3	N	I-Severity
mmHg	NNS	mmhg	mmhg	mmhg	N	I-Severity
diastolic	JJ	diastolic	diastolic	diastol	N	I-Severity
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
maximum	JJ	maximum	maximum	maximum	N	O
decrease	NN	decrease	decrease	decreas	N	O
observed	VBD	observed	observed	observ	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
hour	NN	hour	hour	hour	N	O
after	IN	after	after	after	N	O
dosing	VBG	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
this	DT	this	this	thi	N	O
normally	RB	normally	normally	normal	N	O
would	MD	would	would	would	N	O
be	VB	be	be	be	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
of	IN	of	of	of	N	O
little	JJ	little	little	littl	N	O
consequence	NN	consequence	consequence	consequ	N	O
in	IN	in	in	in	N	O
most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
carefully	RB	carefully	carefully	care	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
affected	VBN	affected	affected	affect	N	O
adversely	RB	adversely	adversely	advers	N	O
by	IN	by	by	by	N	O
such	JJ	such	such	such	N	O
vasodilatory	JJ	vasodilatory	vasodilatory	vasodilatori	N	O
effects	NNS	effects	effect	effect	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
sexual	JJ	sexual	sexual	sexual	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
Inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O

STENDRA	NNP	stendra	stendra	stendra	N	O
metabolism	NN	metabolism	metabolism	metabol	N	O
is	VBZ	is	is	is	N	O
principally	RB	principally	principally	princip	N	O
mediated	VBN	mediated	mediated	mediat	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
CYP450	NNP	cyp450	cyp450	cyp450	N	O
isoform	NN	isoform	isoform	isoform	N	O
3	CD	3	3	3	N	O
A4	NNP	a4	a4	a4	N	O
(	(	(	(	(	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
may	MD	may	may	may	N	O
reduce	VB	reduce	reduce	reduc	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
clearance	NN	clearance	clearance	clearanc	N	O
and	CC	and	and	and	N	O
increase	VB	increase	increase	increas	N	O
plasma	JJ	plasma	plasma	plasma	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
avanafil	NN	avanafil	avanafil	avanafil	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
ketoconazole	NN	ketoconazole	ketoconazole	ketoconazol	N	O
,	,	,	,	,	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
,	,	,	,	,	N	O
atazanavir	NN	atazanavir	atazanavir	atazanavir	N	O
,	,	,	,	,	N	O
clarithromycin	NN	clarithromycin	clarithromycin	clarithromycin	N	O
,	,	,	,	,	N	O
indinavir	NN	indinavir	indinavir	indinavir	N	O
,	,	,	,	,	N	O
itraconazole	NN	itraconazole	itraconazole	itraconazol	N	O
,	,	,	,	,	N	O
nefazodone	NN	nefazodone	nefazodone	nefazodon	N	O
,	,	,	,	,	N	O
nelfinavir	RB	nelfinavir	nelfinavir	nelfinavir	N	O
,	,	,	,	,	N	O
saquinavir	NN	saquinavir	saquinavir	saquinavir	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
telithromycin	NN	telithromycin	telithromycin	telithromycin	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
[	NNP	[	[	[	N	O
seeDrug	JJ	seedrug	seedrug	seedrug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
moderate	JJ	moderate	moderate	moder	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
erythromycin	NN	erythromycin	erythromycin	erythromycin	N	O
,	,	,	,	,	N	O
amprenavir	NN	amprenavir	amprenavir	amprenavir	N	O
,	,	,	,	,	N	O
aprepitant	NN	aprepitant	aprepitant	aprepit	N	O
,	,	,	,	,	N	O
diltiazem	NN	diltiazem	diltiazem	diltiazem	N	O
,	,	,	,	,	N	O
fluconazole	NN	fluconazole	fluconazole	fluconazol	N	O
,	,	,	,	,	N	O
fosamprenavir	NN	fosamprenavir	fosamprenavir	fosamprenavir	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
verapamil	NN	verapamil	verapamil	verapamil	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
maximum	NN	maximum	maximum	maximum	N	O
recommended	VBD	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
is	VBZ	is	is	is	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
not	RB	not	not	not	N	O
to	TO	to	to	to	N	O
exceed	VB	exceed	exceed	exceed	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
[	JJ	[	[	[	N	O
seeDrug	JJ	seedrug	seedrug	seedrug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Prolonged	JJ	prolonged	prolonged	prolong	N	O
Erection	NN	erection	erection	erect	N	O

Prolonged	VBN	prolonged	prolonged	prolong	N	B-AdverseReaction
erection	NN	erection	erection	erect	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	B-Severity
hours	NNS	hours	hour	hour	N	I-Severity
and	CC	and	and	and	N	O
priapism	NN	priapism	priapism	priapism	Y	B-AdverseReaction
(	(	(	(	(	N	O
painful	JJ	painful	painful	pain	N	B-AdverseReaction
erections	NNS	erections	erection	erect	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	B-Severity
hours	NNS	hours	hour	hour	N	I-Severity
in	IN	in	in	in	N	O
duration	NN	duration	duration	durat	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
erection	NN	erection	erection	erect	N	O
that	WDT	that	that	that	N	O
persists	VBZ	persists	persists	persist	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
4	CD	4	4	4	N	O
hours	NNS	hours	hour	hour	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
assistance	NN	assistance	assistance	assist	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
not	RB	not	not	not	N	O
treated	VBN	treated	treated	treat	N	O
immediately	RB	immediately	immediately	immedi	N	O
,	,	,	,	,	N	O
penile	JJ	penile	penile	penil	N	O
tissue	NN	tissue	tissue	tissu	N	O
damage	NN	damage	damage	damag	N	O
and	CC	and	and	and	N	O
permanent	JJ	permanent	permanent	perman	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
potency	NN	potency	potency	potenc	N	O
could	MD	could	could	could	N	O
result	VB	result	result	result	N	O
.	.	.	.	.	N	O

STENDRA	NNP	stendra	stendra	stendra	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
anatomical	JJ	anatomical	anatomical	anatom	N	O
deformation	NN	deformation	deformation	deform	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
penis	NN	penis	penis	peni	N	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
angulation	NN	angulation	angulation	angul	N	O
,	,	,	,	,	N	O
cavernosal	JJ	cavernosal	cavernosal	cavernos	N	O
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
Peyronie	NNP	peyronie	peyronie	peyroni	N	O
's	POS	's	's	's	N	O
disease	NN	disease	disease	diseas	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
conditions	NNS	conditions	condition	condit	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
priapism	VB	priapism	priapism	priapism	Y	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
sickle	NN	sickle	sickle	sickl	N	O
cell	NN	cell	cell	cell	N	O
anemia	NN	anemia	anemia	anemia	Y	O
,	,	,	,	,	N	O
multiple	JJ	multiple	multiple	multipl	N	O
myeloma	NN	myeloma	myeloma	myeloma	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
Eye	NNP	eye	eye	eye	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
advise	VB	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
stop	VB	stop	stop	stop	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
seek	VB	seek	seek	seek	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
sudden	JJ	sudden	sudden	sudden	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
both	DT	both	both	both	N	O
eyes	NNS	eyes	eye	eye	N	O
.	.	.	.	.	N	O

Such	JJ	such	such	such	N	O
an	DT	an	an	an	N	O
event	NN	event	event	event	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
arteritic	JJ	arteritic	arteritic	arterit	N	I-AdverseReaction
anterior	JJ	anterior	anterior	anterior	N	I-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
optic	JJ	optic	optic	optic	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
NAION	NNP	naion	naion	naion	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
rare	JJ	rare	rare	rare	N	O
condition	NN	condition	condition	condit	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
that	WDT	that	that	that	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
rarely	RB	rarely	rarely	rare	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
in	IN	in	in	in	N	O
temporal	JJ	temporal	temporal	tempor	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
published	JJ	published	published	publish	N	O
literature	NN	literature	literature	literatur	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
annual	JJ	annual	annual	annual	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	O
is	VBZ	is	is	is	N	O
2.5	CD	2.5	2.5	2.5	N	O
-	:	-	-	-	N	O
11.8	CD	11.8	11.8	11.8	N	O
cases	NNS	cases	case	case	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
in	IN	in	in	in	N	O
males	NNS	males	male	male	N	O
aged	VBN	aged	aged	age	N	O
50	CD	50	50	50	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
observational	JJ	observational	observational	observ	N	O
study	NN	study	study	studi	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
whether	IN	whether	whether	whether	N	O
recent	JJ	recent	recent	recent	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
suggest	VBP	suggest	suggest	suggest	N	O
an	DT	an	an	an	N	O
approximate	JJ	approximate	approximate	approxim	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	JJ	fold	fold	fold	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	B-AdverseReaction
within	IN	within	within	within	N	O
5	CD	5	5	5	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
lives	NNS	lives	life	live	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	I-DrugClass
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

From	IN	from	from	from	N	O
this	DT	this	this	thi	N	O
information	NN	information	information	inform	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
related	VBN	related	related	relat	N	O
directly	RB	directly	directly	directli	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
[	VBP	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
their	PRP$	their	their	their	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
NAION	NNP	naion	naion	naion	Y	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
adversely	RB	adversely	adversely	advers	N	O
affected	VBN	affected	affected	affect	N	O
by	IN	by	by	by	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

Individuals	NNS	individuals	individual	individu	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
already	RB	already	already	alreadi	N	O
experienced	VBN	experienced	experienced	experienc	N	O
NAION	NNP	naion	naion	naion	Y	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
NAION	NNP	naion	naion	naion	Y	O
recurrence	NN	recurrence	recurrence	recurr	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
only	RB	only	only	onli	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
anticipated	JJ	anticipated	anticipated	anticip	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
.	.	.	.	.	N	O

Individuals	NNS	individuals	individual	individu	N	O
with	IN	with	with	with	N	O
"	NNP	"	"	"	N	O
crowded	VBD	crowded	crowded	crowd	N	O
"	NNP	"	"	"	N	O
optic	JJ	optic	optic	optic	N	O
disc	NN	disc	disc	disc	N	O
are	VBP	are	are	are	N	O
also	RB	also	also	also	N	O
considered	VBN	considered	considered	consid	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
NAION	NNP	naion	naion	naion	Y	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
,	,	,	,	,	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
evidence	NN	evidence	evidence	evid	N	O
is	VBZ	is	is	is	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
to	TO	to	to	to	N	O
support	VB	support	support	support	N	O
screening	NN	screening	screening	screen	N	O
of	IN	of	of	of	N	O
prospective	JJ	prospective	prospective	prospect	N	O
users	NNS	users	user	user	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
this	DT	this	this	thi	N	O
uncommon	JJ	uncommon	uncommon	uncommon	N	O
condition	NN	condition	condition	condit	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Sudden	JJ	sudden	sudden	sudden	N	O
Hearing	NNP	hearing	hearing	hear	N	O
Loss	NNP	loss	loss	loss	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hearing	NN	hearing	hearing	hear	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
tinnitus	NN	tinnitus	tinnitus	tinnitu	Y	B-AdverseReaction
or	CC	or	or	or	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
whether	IN	whether	whether	whether	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
related	VBN	related	related	relat	N	O
directly	RB	directly	directly	directli	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
[	VBP	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
stop	VB	stop	stop	stop	N	O
taking	VBG	taking	taking	take	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
and	CC	and	and	and	N	O
seek	JJ	seek	seek	seek	N	O
prompt	NN	prompt	prompt	prompt	N	O
medical	JJ	medical	medical	medic	N	O
attention	NN	attention	attention	attent	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Alpha	NNP	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
Blockers	NNS	blockers	blocker	blocker	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Antihypertensives	NNS	antihypertensives	antihypertensive	antihypertens	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
discuss	VB	discuss	discus	discuss	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
to	TO	to	to	to	N	O
augment	VB	augment	augment	augment	N	O
the	DT	the	the	the	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
-	:	-	-	-	N	O
lowering	VBG	lowering	lowering	lower	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
alpha	NN	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
[	VBP	[	[	[	N	O
seeDrug	JJ	seedrug	seedrug	seedrug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
andClinical	JJ	andclinical	andclinical	andclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Caution	NN	caution	caution	caution	N	O
is	VBZ	is	is	is	N	O
advised	VBN	advised	advised	advis	N	O
when	WRB	when	when	when	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
are	VBP	are	are	are	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
.	.	.	.	.	N	O

Phosphodiesterase	NNP	phosphodiesterase	phosphodiesterase	phosphodiesteras	N	O
type	VBD	type	type	type	N	O
5	CD	5	5	5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
alpha	SYM	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
blocking	NN	blocking	blocking	block	N	O
agents	NNS	agents	agent	agent	N	O
are	VBP	are	are	are	N	O
both	DT	both	both	both	N	O
vasodilators	NNS	vasodilators	vasodilator	vasodil	N	O
with	IN	with	with	with	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
-	:	-	-	-	N	O
lowering	NN	lowering	lowering	lower	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
vasodilators	NNS	vasodilators	vasodilator	vasodil	N	O
are	VBP	are	are	are	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
additive	JJ	additive	additive	addit	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
anticipated	VBN	anticipated	anticipated	anticip	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
two	CD	two	two	two	N	O
drug	NN	drug	drug	drug	N	O
classes	NNS	classes	class	class	N	O
can	MD	can	can	can	N	B-Factor
lower	VB	lower	lower	lower	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
significantly	RB	significantly	significantly	significantli	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
lightheadedness	NN	lightheadedness	lightheadedness	lightheaded	Y	B-AdverseReaction
,	,	,	,	,	N	O
fainting	VBG	fainting	fainting	faint	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
stable	JJ	stable	stable	stabl	N	O
on	IN	on	on	on	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
demonstrate	VBP	demonstrate	demonstrate	demonstr	N	O
hemodynamic	JJ	hemodynamic	hemodynamic	hemodynam	N	O
instability	NN	instability	instability	instabl	N	O
on	IN	on	on	on	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
alone	RB	alone	alone	alon	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	B-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
stable	JJ	stable	stable	stabl	N	O
on	IN	on	on	on	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
lowest	JJS	lowest	lowest	lowest	N	O
dose	NN	dose	dose	dose	N	O
(	(	(	(	(	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
already	RB	already	already	alreadi	N	O
taking	VBG	taking	taking	take	N	O
an	DT	an	an	an	N	O
optimized	VBN	optimized	optimized	optim	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
alpha	SYM	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
lowest	JJS	lowest	lowest	lowest	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Stepwise	NNP	stepwise	stepwise	stepwis	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
alpha	JJ	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blocker	NN	blocker	blocker	blocker	N	O
dose	NN	dose	dose	dose	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
further	JJ	further	further	further	N	O
lowering	NN	lowering	lowering	lower	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
when	WRB	when	when	when	N	O
taking	VBG	taking	taking	take	N	O
a	DT	a	a	a	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

Safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
combined	JJ	combined	combined	combin	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
and	CC	and	and	and	N	O
alpha	SYM	alpha	alpha	alpha	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
affected	VBN	affected	affected	affect	N	O
by	IN	by	by	by	N	O
other	JJ	other	other	other	N	O
variables	NNS	variables	variable	variabl	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
intravascular	JJ	intravascular	intravascular	intravascular	N	O
volume	NN	volume	volume	volum	N	O
depletion	NN	depletion	depletion	deplet	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
drugs	NNS	drugs	drug	drug	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O

Alcohol	NN	alcohol	alcohol	alcohol	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
aware	JJ	aware	aware	awar	N	O
that	IN	that	that	that	N	O
both	DT	both	both	both	N	O
alcohol	NN	alcohol	alcohol	alcohol	N	O
and	CC	and	and	and	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
including	VBG	including	including	includ	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
act	NN	act	act	act	N	O
as	IN	as	a	as	N	O
vasodilators	NNS	vasodilators	vasodilator	vasodil	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
vasodilators	NNS	vasodilators	vasodilator	vasodil	N	O
are	VBP	are	are	are	N	O
taken	VBN	taken	taken	taken	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
-	:	-	-	-	N	O
pressure	NN	pressure	pressure	pressur	N	O
-	:	-	-	-	N	O
lowering	VBG	lowering	lowering	lower	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
individual	JJ	individual	individual	individu	N	O
compound	NN	compound	compound	compound	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
increased	VBN	increased	increased	increas	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
inform	VB	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
that	IN	that	that	that	N	O
substantial	JJ	substantial	substantial	substanti	N	O
consumption	NN	consumption	consumption	consumpt	N	O
of	IN	of	of	of	N	O
alcohol	NN	alcohol	alcohol	alcohol	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	O
units	NNS	units	unit	unit	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
,	,	,	,	,	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
standing	VBG	standing	standing	stand	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	O
[	NNP	[	[	[	N	O
seeDrug	NN	seedrug	seedrug	seedrug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
andClinical	JJ	andclinical	andclinical	andclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Other	JJ	other	other	other	N	O
PDE5	NNP	pde5	pde5	pde5	N	O
Inhibitors	NNPS	inhibitors	inhibitor	inhibitor	N	O
or	CC	or	or	or	N	O
Erectile	NNP	erectile	erectile	erectil	N	O
Dysfunction	NNP	dysfunction	dysfunction	dysfunct	N	O
Therapies	NNP	therapies	therapy	therapi	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
combinations	NNS	combinations	combination	combin	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
treatments	NNS	treatments	treatment	treatment	N	O
for	IN	for	for	for	N	O
ED	NNP	ed	ed	ed	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
such	JJ	such	such	such	N	O
combinations	NNS	combinations	combination	combin	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
Bleeding	VBG	bleeding	bleeding	bleed	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
peptic	JJ	peptic	peptic	peptic	N	O
ulceration	NN	ulceration	ulceration	ulcer	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	B-Factor
vitro	JJ	vitro	vitro	vitro	N	I-Factor
studies	NNS	studies	study	studi	N	I-Factor
with	IN	with	with	with	N	O
human	JJ	human	human	human	N	O
platelets	NNS	platelets	platelet	platelet	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
potentiates	VBZ	potentiates	potentiates	potenti	N	B-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
anti	JJ	anti	anti	anti	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
aggregatory	JJ	aggregatory	aggregatory	aggregatori	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
sodium	NN	sodium	sodium	sodium	Y	I-AdverseReaction
nitroprusside	NN	nitroprusside	nitroprusside	nitroprussid	N	I-AdverseReaction
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
nitric	JJ	nitric	nitric	nitric	N	O
oxide	NN	oxide	oxide	oxid	N	O
[	NNP	[	[	[	N	O
NO	NNP	no	no	no	N	O
]	NNP	]	]	]	N	O
donor	NN	donor	donor	donor	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Counseling	JJ	counseling	counseling	counsel	N	O
Patients	NNS	patients	patient	patient	N	O
about	IN	about	about	about	N	O
Sexually	NNP	sexually	sexually	sexual	N	O
Transmitted	NNP	transmitted	transmitted	transmit	N	O
Diseases	NNP	diseases	disease	diseas	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
STENDRA	NNP	stendra	stendra	stendra	N	O
offers	VBZ	offers	offer	offer	N	O
no	DT	no	no	no	N	O
protection	NN	protection	protection	protect	N	O
against	IN	against	against	against	N	O
sexually	RB	sexually	sexually	sexual	N	O
transmitted	JJ	transmitted	transmitted	transmit	N	O
diseases	NNS	diseases	disease	diseas	N	O
.	.	.	.	.	N	O

Counseling	VBG	counseling	counseling	counsel	N	O
patients	NNS	patients	patient	patient	N	O
about	IN	about	about	about	N	O
the	DT	the	the	the	N	O
protective	JJ	protective	protective	protect	N	O
measures	NNS	measures	measure	measur	N	O
necessary	JJ	necessary	necessary	necessari	N	O
to	TO	to	to	to	N	O
guard	VB	guard	guard	guard	N	O
against	IN	against	against	against	N	O
sexually	RB	sexually	sexually	sexual	N	O
transmitted	JJ	transmitted	transmitted	transmit	N	O
diseases	NNS	diseases	disease	diseas	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Human	NNP	human	human	human	N	O
Immunodeficiency	NNP	immunodeficiency	immunodeficiency	immunodefici	Y	O
Virus	NNP	virus	virus	viru	N	O
(	(	(	(	(	N	O
HIV	NNP	hiv	hiv	hiv	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

